Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).

Carlo Pallotto,Pierluigi Blanc,Sara Esperti,Lorenzo Roberto Suardi,Andrea Gabbuti,Francesca Vichi,Lorenzo Mecocci, Anna Degli Esposti,Piera Pierotti, Letizia Attala,Elena Salomoni,Filippo Baragli,Daniela Francisci,Massimo Antonio Di Pietro

The Journal of infection（2021）

引用 17|浏览3

暂无评分

摘要

•Remdesivir is the only antiviral approved for COVID-19.•Remdesivir treatment was associated with transient bradycardia.•Bradycardia did not cause any severe clinical manifestation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要